Article
Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
Hepato-gastroenterology - 1 Jun 2014
Ascione Antonio, Bruno Savino, Coppola Carmine, Mangia Alessandra, Orlandini Alessandra, Schmitz Manuela, Deodato Barbara, Puoti Massimo
Abstract excerpt
BACKGROUND/AIMS: Within Europe, Italy has the highest incidence of HCV. PROPHESYS was a large, non-interventional, multinational cohort study of patients treated with peginterferon alfa-2a or -2b/ribavirin for CHC; 22.4% of patients were from Italian centers. This sub-analysis evaluates real-life practice and treatment outcomes in Italy. METHODOLOGY: The PROPHESYS 2 cohort included 1604 HCV mono-infected,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.